Page last updated: 2024-08-26

sr141716 and Hypertension, Portal

sr141716 has been researched along with Hypertension, Portal in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lotersztajn, S; Mallat, A	1
Deveaux, V; Hezode, C; Lotersztajn, S; Mallat, A; Teixeira-Clerc, F; Tran van Nhieu, J	1
Garcia, N; Járai, Z; Kunos, G; Mirshahi, F; Sanyal, AJ	1

Reviews

1 review(s) available for sr141716 and Hypertension, Portal

Article	Year
Endocannabinoids and their role in fatty liver disease. Digestive diseases (Basel, Switzerland), 2010, Volume: 28, Issue:1 Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Fatty Liver; Humans; Hypertension, Portal; Inflammation; Insulin Resistance; Liver Cirrhosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant	2010

Article

Year

Endocannabinoids and their role in fatty liver disease.

Digestive diseases (Basel, Switzerland), 2010, Volume: 28, Issue:1

Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Fatty Liver; Humans; Hypertension, Portal; Inflammation; Insulin Resistance; Liver Cirrhosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant

2010

Other Studies

2 other study(ies) available for sr141716 and Hypertension, Portal

Article	Year
[Endocannabinoids: therapeutic perspectives in chronic liver diseases]. Gastroenterologie clinique et biologique, 2007, Volume: 31, Issue:3 Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant	2007
Systemic and portal hemodynamic effects of anandamide. American journal of physiology. Gastrointestinal and liver physiology, 2001, Volume: 280, Issue:1 Topics: Animals; Arachidonic Acids; Blood Pressure; Calcium Channel Blockers; Cannabinoids; Cardiac Output; Cyclooxygenase Inhibitors; Endocannabinoids; Enzyme Inhibitors; Heart Rate; Hypertension, Portal; Indomethacin; Liver Circulation; Male; Masoprocol; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Piperidines; Polyunsaturated Alkamides; Portal Vein; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Splanchnic Circulation	2001

Article

Year

[Endocannabinoids: therapeutic perspectives in chronic liver diseases].

Gastroenterologie clinique et biologique, 2007, Volume: 31, Issue:3

Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant

2007

Systemic and portal hemodynamic effects of anandamide.

American journal of physiology. Gastrointestinal and liver physiology, 2001, Volume: 280, Issue:1

Topics: Animals; Arachidonic Acids; Blood Pressure; Calcium Channel Blockers; Cannabinoids; Cardiac Output; Cyclooxygenase Inhibitors; Endocannabinoids; Enzyme Inhibitors; Heart Rate; Hypertension, Portal; Indomethacin; Liver Circulation; Male; Masoprocol; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Piperidines; Polyunsaturated Alkamides; Portal Vein; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Splanchnic Circulation

2001